Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
STAMFORD, Conn., April 27, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, May 4, 2017, at 4:30 p.m. ET to report first quarter 2017 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 10052639. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara Therapeutics is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
